Peer-influenced content. Sources you trust. No registration required. This is HCN.

Renal & Urology NewsProstate Cancer Survival Differs by Site of Visceral Metastases

Lung-Only Visceral Metastases in Metastatic Prostate Cancer Associated with Best Overall Survival

Understanding the prognostic factors in metastatic prostate cancer is essential for tailored patient care. A new study reveals that patients with lung-only visceral metastases have better overall survival rates than those with metastases in other visceral sites such as liver and brain.

HCN Medical Memo
This study offers crucial insights into tailoring patient care for those with prostate cancer. Knowing that lung-only visceral metastases are associated with better survival outcomes can inform treatment planning and patient counseling. Additionally, this study should serve as a catalyst for more focused research on dose intensification and individual patient strategies.

Key Points:
  • The study included 1,827 patients with metastatic prostate cancer and found that the median overall survival (OS) time was 22 months.
  • Patients with lung-only metastases had a median OS time of 33 months, whereas those with liver-only or brain-only metastases had median OS times of 15 and 16 months, respectively.
  • Men with two or more visceral metastatic sites had a median OS time of just 15 months.
  • Among those with lung-only metastases, the highest OS was observed in patients with concurrent non-visceral metastases in lymph nodes only, with a median OS of 57 months.
  • Multivariable Cox regression models showed that liver-only, brain-only, and 2 or more visceral metastases were associated with 2.1-, 2.1, and 2.0-fold increased risks of all-cause mortality, respectively.
Additional Points:
  • The study used data from the 2010-2016 Surveillance, Epidemiology and End Results (SEER) database.
  • Of the 1,827 patients, 57% had lung-only metastases, 25% liver-only, 7% brain-only, and 11% had metastases in two or more visceral sites.
  • The study lacked specific details on the number of metastases at each site and did not include information on treatment type, dose, and duration.

Among men with lung-only metastases and concurrent non-visceral metastases in lymph nodes only, the median overall survival was an impressive 57 months.

More on Prostate Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form